Year 2017: The Game-Changing Year?, page-3

I think the sozo sale won't be the next catalyst. The sozo development will take some fine tuning first so that it can both cater for CHF and lymphedema and general fitness.

The key announcement that will spring the price up again is one whereby Sozo is shown to predict a CHF patient's wellbeing. FDA approval becomes a no brainer if test results validates the theory that BIS has diagnostic ability.

Sozo for use for lymphedema will be a no brainer as replacement for L-Dex machines. However I got a feeling they'll still sell Ldex until FDA approves Sozo as equally capable of doing the same job. And the critical path may be proving Sozo could be used both for CHF and lymphedema.